BARNASE-BARSTAR SPECIFIC INTERACTION REGULATES CAR-T CELLS CYTOTOXIC ACTIVITY TOWARD MALIGNANCY

Roman S. Kalinin; Калинин Р. С.; Alexander G. Gabibov; Габибов А. Г.; Nikolay V. Gnuchev; Гнучев Н. В.; Elena Khurs; Хурс Е. Н.; Vera D. Knorre; Кнорре В. Д.; Stanislav S. Terekhov; Терехов С. С.; Mikhail A. Maschan; Масчан М. А.; Alexandr S. Chernov; Чернов А. С.; Georgij B. Telegin; Телегин Г. Б.; Alexey A. Belogurov; Белогуров А. А.; Anastasiia M. Moysenovich; Мойсенович А. М.; Igor A. Yaroshevich; Ярошевич И. А.; Dmitry V. Volkov; Волков Д. В.; Elena V. Konovalova; Коновалова Е. В.; Alexey Schulga; Шульга А. А.; Valeria M. Ukrainskay; Украинская В. М.; Yuri P. Rubtsov; Рубцов Ю. П.; Victoria O. Shipunova; Шипунова В. О.; Sergey M. Deyev; Деев С. М.

doi:10.31857/S2686738922600972

BARNASE-BARSTAR SPECIFIC INTERACTION REGULATES CAR-T CELLS CYTOTOXIC ACTIVITY TOWARD MALIGNANCY

Authors: Kalinin R.S.¹, Gabibov A.G.¹^,2, Gnuchev N.V.³, Khurs E.³, Knorre V.D.¹, Terekhov S.S.¹^,2, Maschan M.A.⁴, Chernov A.S.¹, Telegin G.B.¹, Belogurov A.A.¹^,2, Moysenovich .M.², Yaroshevich I.A.², Volkov D.V.¹, Konovalova E.V.¹, Schulga .¹, Ukrainskay V.M.¹^,4, Rubtsov Y.P.¹, Shipunova V.O.¹, Deyev S.M.¹^,5
Affiliations:
1. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
2. M.V. Lomonosov Moscow State University
3. Engelhardt Institute of molecular Biology, Russian Academy of Sciences
4. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology
5. National Research University Higher School of Economics
Issue: Vol 510, No 1 (2023)
Pages: 231-235
Section: Articles
URL: https://journals.rcsi.science/2686-7389/article/view/135688
DOI: https://doi.org/10.31857/S2686738922600972
EDN: https://elibrary.ru/QFANKV
ID: 135688

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The development of CAR-T specific therapy made a revolution in modern oncology. Despite the pronounced therapeutic effects, this novel approach displayed several crucial limitations caused by the complications in pharmacokinetics and pharmacodynamics controls. The presence of the several severe medical complications of CAR-T therapy initiated a set of attempts aimed to regulate their activity in vivo. We propose to apply the barnase-barstar system to control the cytotoxic antitumor activity of CAR-T cells. To menage the regulation targeting effect of the system we propose to use barstar-modified CAR -T cells together with barnase-based molecules. Barnase was fused with designed ankyrin repeat proteins (DARPins) specific to tumor antigens HER2 (human epidermal growth factor receptor 2) The application of the system demonstrates the pronounced regulatory effects of CAR-T targeting.

Keywords

Barnase-barstar interaction, DARPins, CAR T cells, solid tumors

References

Weber E.W., Maus M.V., Mackall C.L., The Emerging Landscape of Immune Cell Therapies. Cell. 2020. V. 181. P. 46–62.
Stepanov A.V., et al., Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci Adv 2018.V. 4. P. eaau4580.
Turtle C.J., et al., Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol. 2017. V. 35. P. 3010–3020.
Mancikova V., Smida M., Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2021. V. 22. P. 5536.
Калинин Р.С., et al., Молекулярные подходы к безопасной и контролируемой Т-клеточной терапии. Acta Naturae. 2018. Т. 10. С. 16–23.
Schultz L.M., et al., Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022. V. 40. P. 945–955.
Davila M.L., et al., Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med. 2014. V. 6. P. 224ra25.
Schuster S.J., et al., Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017. V. 377. P. 2545–2554.
Neelapu S.S., et al., Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017. V. 377. P. 2531–2544.
Urbanska K., et al., A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012. V. 72. P. 1844–1852.
Tamada K., et al., Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 2012. V. 18. P. 6436–6445.
Ma J.S.Y., et al., Versatile strategy for controlling the specificity and activity of engineered T cells. Proc. Natl. Acad. Sci. U.S.A. 2016. V. 113. P. E450–458.
Rodgers D.T., et al., Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl. Acad. Sci. U.S.A. 2016. V. 113. P. E459–468.
Cho J.H., Collins J.J., Wong W.W., Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell. 2018. V. 173. P. 1426–1438.e11.
Hartley R.W., “[38] – Barnase–Barstar Interaction” in Methods in Enzymology, Ribonucleases – Part A., A.W. Nicholson, Ed. (Academic Press, 2001). P. 599–611.
Deyev S.M., Waibel R., Lebedenko E.N., Schubiger A.P., Plückthun A., Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol. 2003. V. 21. P. 1486–1492.
Tolmachev V.M., Chernov V.I., Deyev S.M., Targeted nuclear medicine. Seek and destroy. Russ. Chem. Rev. 2022. V. 91. P. RCR5034.
Steiner D., Forrer P., Plückthun A., Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol. 2008. V. 382. P. 1211–1227.
Zahnd C., et al., A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to Her2. Journal of Molecular Biology. 2007. V. 369. P. 1015–1028.
Stepanov A.V., et al., Switchable targeting of solid tumors by BsCAR T cells. Proc Natl Acad Sci U S A. 2022. V. 119. P. e2210562119.
Zdobnova T., et al., A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins. Oncotarget. 2015. V. 6. P. 30919–30928.